PTAB Upholds Vimovo Patent Claims Challenged By LupinPozen Inc. fended off further challenges to patents covering its arthritis and ulcer drug Vimovo on Tuesday, when the Patent Trial and Appeal Board decided that Lupin Ltd. had not shown that the challenged claims in two patents were invalid.
The final decisions came less than a week after PTAB upheld the validity of another Vimovo patent in an inter partes review requested by the Coalition for Affordable Drugs, an organization started by hedge fund manager Kyle Bass.
Both patents challenged by Lupin disclosed pharmaceutical compositions...
To view the full article, register now.
Already a subscriber? Click here to view full article